Month: April 2020

No. 5/2020Copenhagen, 20 April 2020Lauritz.com Group has appointed the internationally acknowledged M&A consultancy GCA Altium to actively pursue the strategic possibilities for strengthening the capital base of the company and redeem the bond debt. The appointment has been made in agreement with a group of bondholders holding approx. 47% of the outstanding bonds. The same bondholders have also agreed that they will not propose or support any proposal to activate the pledges. This agreement applies until December 31st 2020.Bengt Sundström, Chairman of the boardCarsten Rysgaard, CEOPreben Vinkler Lindgaard, CFOFor press enquiries, please contact:Susanne Sandsberg+45 26891909  E-mail: press@lauritz.comFor other enquiries, please contact:Preben Vinkler LindgaardCFOPreben@lauritz.comCertified Adviser: Erik Penser Bank ABTelephone number:...

Amundi: The Ordinary and Extraordinary General Meeting of shareholders, 12th May 2020Arrangements for making preparatory documentsavailable and consulting them

Amundi : Assemblée générale Mixte Ordinaire et Extraordinaire du 12 mai 2020Modalités de mise à disposition ou de consultationdes documents préparatoires

PORTLAND, Ore., April 20, 2020 (GLOBE NEWSWIRE) — Northwest Natural Holding Company (NYSE: NWN) (NW Natural Holdings) announced today it will issue its first quarter 2020 earnings release and conduct an analyst conference call and webcast to review results at 8 a.m. Pacific Time (11 a.m. Eastern Time) on Friday, May 8, 2020.To hear the conference by webcast, log on to NW Natural Holdings’ corporate website at nwnaturalholdings.com. To hear the conference call by phone, please dial 1-866-267-6789 within the United States and 1-855-669-9657 from Canada. International callers can dial 1-412-902-4110.To access the conference replay, please call 1-877-344-7529 within the United States and enter the conference identification pass code 10141985. To hear the replay from Canada, please dial 1-855-669-9658 and from international locations,...

Gabriel Holding A/S realiserer et solidt første halvår af regnskabsåret 2019/20, men udbrud af coronavirus (COVID-19) påvirker imidlertid de markedsmæssige forudsætninger for selskabet negativt. Forventningerne til regnskabsåret 2019/20 opdateres som følge heraf.Gabriel Holding A/S suspenderede d. 20. marts 2020 midlertidigt de finansielle forventninger til regnskabsåret 2019/20.I henhold til koncernens finanskalender offentliggøres regnskabet for årets første halvår (1. oktober 2019 – 31. marts 2020) d. 30. april 2020. Halvårsrapporten offentliggøres i sin helhed på denne dato, men resume for perioden samt opdatering af de finansielle forventninger offentliggøres hermed.ResuméOmsætningen steg med 74,2 mio.kr. (22%) til 418,0 mio. kr. (343,7 mio. kr.).I 2. kvartal udgjorde stigningen 20% til 213,6 mio. kr. (178,4 mio. kr.)Resultat af...

Gabriel Holding A/S realises a solid first half of the 2019/20 financial year but the outbreak of coronavirus (Covid-19) has an adverse effect on market conditions for the company. As a result, the expectations for the 2019/20 financial year are updated.On 20 March 2020, Gabriel Holding A/S temporarily suspended its financial expectations for the 2019/20 financial year.In accordance with the Group’s financial calendar, the financial statements for the first half of the year (1 October 2019 to 31 March 2020) will be published on 30 April 2020. The interim report will be published in its entirety on that date, but a summary for the period and an update on financial expectations are published below.SummaryRevenue increased by DKK 74.2 million (22%) to DKK 418.0 million (DKK 343.7 million)The increase in the second quarter was 20% to DKK...

April 20, 2020N.B. English translation is for convenience purposes onlyThe shareholders in Aino Health AB (publ), reg. no. 559063-5073 (the “Company”) are hereby convened to the annual general meeting on Monday 18 May 2020 at 17.00 at the Company’s office at Skeppargatan 8, level two, Stockholm.To reduce the risk of the spread of COVID-19 (the coronavirus), no food or drink will be served at the annual general meeting and the number of non-shareholders present will be limited. Shareholders with cold-like or flu-like symptoms, including mild symptoms, are asked to participate via proxy. Shareholders belonging to a risk group are also invited to participate via proxy instead of in person. The Company closely monitors the situation regarding the COVID-19 outbreak and will post information on the Company’s website (www.ainohealth.com) if...

20 april, 2020Aktieägarna i Aino Health AB (publ), org.nr 559063-5073 (”Bolaget”) kallas härmed till årsstämma måndagen den 18 maj 2020 klockan 17.00 i Bolagets lokaler på Skeppargatan 8, våning två, Stockholm.I syfte att minska risken för spridning av covid-19 (coronaviruset) kommer antalet närvarande deltagare som inte är aktieägare att begränsas, ingen mat eller dryck kommer att serveras och planerade anföranden kommer att begränsas i tid. Aktieägare med förkylnings- eller influensaliknande symptom, även milda sådana, ombeds delta via ombud. Även aktieägare som tillhör en riskgrupp uppmanas att delta via ombud i stället för personligen. Bolaget följer noggrant hur situationen kring covid-19 utvecklas och återkommer med information på hemsidan (www.ainohealth.com) om ytterligare åtgärder bedöms nödvändiga.AnmälanAktieägare som önskar...

Seneca Growth Capital VCT Plc (the “Company”)20 April 2020Partial Realisation of Ordinary Share Investment in Omega Diagnostics Group plc, New Ordinary Share Net Asset Value and New B Share Pool InvestmentsThe Board of Seneca Growth Capital VCT Plc have noted the announcements made by Ordinary Share pool investee company, Omega Diagnostics Group plc (“Omega”) on 9 and 20 April 2020.  The first announcement confirmed that Omega had signed a Memorandum of Understanding (“MOU”) with three other companies from across the UK, in conjunction with the University of Oxford to form the UK Rapid Test Consortium (“UK-RTC”) in order to jointly develop and manufacture a COVID-19 Point of Care antibody test as part of the Government’s five pillar national testing strategy for COVID-19. The second announcement...

Company Announcement No. 14 / 2020Announcement is attached. For further information please contact:Martin Riise, Head of Investor Relations, Tel: +45 5339 2250Annika Stern, Investor Relations Officer, Tel: +45 2399 2382Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384About HSO Health Care GmbHFounded in 2007, HSO Health Care GmbH is an Austrian company that focuses on the research and development of probiotics targeting women’s health. The company developed the patented composition Astarte™, a unique probiotic formulation for women´s health supported by science. Since the introduction of the Astarte™ line to the marketplace, demand has experienced explosive growth. In 2019, HSO Health Care’s Astarte™ won the “Probiotic of the Year” award at the NutraIngredients Awards in both the US and in the EU. Further information can be...